Arnold Freedman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma
    K E Abou-Nassar
    Lymphoma Program, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Bone Marrow Transplant 46:1503-9. 2011
  2. ncbi request reprint Non-transplant-related treatment options in follicular lymphoma
    Arnold S Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:53-8. 2006
  3. pmc Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
    Arnold Freedman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:3036-43. 2009
  4. ncbi request reprint Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma
    Iain J Webb
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 8:429-34. 2002
  5. ncbi request reprint Follicular lymphoma: 2011 update on diagnosis and management
    Arnold Freedman
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Hematol 86:768-75. 2011
  6. ncbi request reprint Follicular lymphoma: 2012 update on diagnosis and management
    Arnold Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Am J Hematol 87:988-95. 2012
  7. ncbi request reprint Follicular lymphoma: 2014 update on diagnosis and management
    Arnold Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Am J Hematol 89:429-36. 2014
  8. ncbi request reprint Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy
    Abba C Zubair
    Connell O Reilly Cell Manipulation Core Facility, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Transfusion 44:253-61. 2004
  9. ncbi request reprint B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma
    Eric Jacobsen
    Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 5:711-7. 2004
  10. ncbi request reprint An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma
    Eric Jacobsen
    Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Opin Oncol 16:106-13. 2004

Research Grants

  1. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2001
  2. CpG Plus Rituximab Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2005
  3. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 1999
  4. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2000
  5. Etanercept Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2003

Collaborators

Detail Information

Publications28

  1. pmc (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma
    K E Abou-Nassar
    Lymphoma Program, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Bone Marrow Transplant 46:1503-9. 2011
    ..Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies...
  2. ncbi request reprint Non-transplant-related treatment options in follicular lymphoma
    Arnold S Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:53-8. 2006
  3. pmc Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
    Arnold Freedman
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:3036-43. 2009
    ..To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20(+) follicular lymphoma...
  4. ncbi request reprint Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma
    Iain J Webb
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 8:429-34. 2002
    ..5 days (range, 8-17 days). This nonmagnetic negative-depletion technology is simple, rapid, and effective in depleting target cells to undetectable levels, with excellent recovery of nontarget cells...
  5. ncbi request reprint Follicular lymphoma: 2011 update on diagnosis and management
    Arnold Freedman
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Hematol 86:768-75. 2011
    ..In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon...
  6. ncbi request reprint Follicular lymphoma: 2012 update on diagnosis and management
    Arnold Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Am J Hematol 87:988-95. 2012
    ..In general, cytopenias can occur but constitutional symptoms of fever, night sweats, and weight loss are uncommon...
  7. ncbi request reprint Follicular lymphoma: 2014 update on diagnosis and management
    Arnold Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Am J Hematol 89:429-36. 2014
    ..In general cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon...
  8. ncbi request reprint Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy
    Abba C Zubair
    Connell O Reilly Cell Manipulation Core Facility, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Transfusion 44:253-61. 2004
  9. ncbi request reprint B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma
    Eric Jacobsen
    Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 5:711-7. 2004
    ..We analysed data on the purging of B cells by use of antibodies in the setting of autologous transplantation, with emphasis on the emerging technique of in vivo purging...
  10. ncbi request reprint An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma
    Eric Jacobsen
    Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Opin Oncol 16:106-13. 2004
    ..Also, until recently, allogeneic stem cell transplantation was not an option for most mantle cell lymphoma patients who were too old or infirm to tolerate standard conditioning regimens...
  11. pmc Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
    Jeffrey A Barnes
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Haematologica 98:615-9. 2013
    ..In conclusion, everolimus in combination with rituximab is well tolerated and demonstrates activity in relapsed diffuse large B-cell lymphoma. Further studies of this combination are warranted...
  12. ncbi request reprint Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature
    Eric Jacobsen
    Department of Medical Oncology, Dana Farber Cancer Institute, Havard Medical School, Boston, 02115, USA
    Leuk Lymphoma 46:1663-6. 2005
    ..He is now 6 months into therapy and responding well. A review of the literature demonstrated this to be the first confirmed case of testicular and epididymal involvement with grade I follicular lymphoma...
  13. ncbi request reprint Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution
    Abba Zubair
    Connell O Reilly Cell Manipulation Core Facility and the Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Transfusion 43:614-21. 2003
    ..The aim of this study was to identify factors that predict long-term hematopoietic reconstitution (LHR) following autologous BMT...
  14. doi request reprint Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma
    Ann S LaCasce
    Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Semin Hematol 45:85-9. 2008
    ..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...
  15. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  16. pmc Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:1057-65. 2007
    ..99-8.8, P=.0002). No significant predictors of overall survival were identified. These results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged survival with ABMT in first remission...
  17. ncbi request reprint Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up
    Ama Z S Rohatiner
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 25:2554-9. 2007
    ....
  18. ncbi request reprint Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Room 1 4118C, NY 14642, USA
    Curr Treat Options Oncol 7:276-84. 2006
    ..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...
  19. pmc Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 106:4389-96. 2005
    ..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens...
  20. ncbi request reprint Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:2208-14. 2005
    ..We report the incidence and outcome of solid tumors at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL)...
  21. ncbi request reprint Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Blood 105:489-95. 2005
    ..CpG treatment resulted in no significant toxicity, providing rationale for further testing of this exciting combination immunotherapy approach to NHL...
  22. ncbi request reprint Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Br J Haematol 117:828-34. 2002
    ..Further studies of this rational combination are warranted and ongoing...
  23. ncbi request reprint Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 45:315-20. 2004
    ..003). Outcomes of autologous BMT in patients with disseminated marginal zone NHL are similar to those in follicular NHL, and suggest that certain patients may experience prolonged disease-free survival...
  24. ncbi request reprint Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation
    Edwin P Alyea
    Biol Blood Marrow Transplant 8:601-7. 2002
    ..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates...
  25. ncbi request reprint CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells
    Herve Husson
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Br J Haematol 119:492-5. 2002
    ..The production of CXCL13 by FL cells and CXCL12 by stromal cells probably directs and participates in the accumulation of FL cells within specific anatomic sites...
  26. ncbi request reprint Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome
    Valia S Lestou
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
    Br J Haematol 122:745-59. 2003
    ....
  27. ncbi request reprint Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Pathol 121:701-8. 2004
    ..These observations imply that, similar to the observations in B-cell NHLs occurring with HD, a subset of synchronous and metachronous T-cell NHLs and HD may be related clonally...
  28. ncbi request reprint Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays
    Herve Husson
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Blood 99:282-9. 2002
    ..These findings provide a basis for future studies into the pathogenesis and pathophysiology of FL and may lead to the identification of potential therapeutic targets as well as antigens for immunotherapeutic strategies...

Research Grants5

  1. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2001
    ..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
  2. CpG Plus Rituximab Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2005
    ..This study is a novel approach to treating FL, where augmenting antigen presentation and effector cells may lead to enhanced cytotoxic effects of rituximab and induce anti-tumor immunity. ..
  3. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 1999
    ..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
  4. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2000
    ..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
  5. Etanercept Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2003
    ..This study is a novel approach to treating FL, where targeting the microenvironment of the tumor may inhibit the growth and survival of the neoplastic cells. ..